BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
IMVT upcoming catalysts
Immunovant Sciences GmbH: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 5 readout(s) and 0 FDA event(s). Subscribe to IMVT (.ics).
Drugs: Batoclimab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P2 | Immunovant Sciences GmbH IMVT | NCT06980805 A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | active not recruiting | 56 |
| 2026-07-20 | P2 | Immunovant Sciences GmbH IMVT | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP | Chronic Inflammatory Demyelinating Polyneuropathy | terminated | 94 |
| 2026-07-16 | P2 | Immunovant Sciences GmbH IMVT | NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyneuropathy | terminated | 26 |
| 2026-04-02 | P3 | Immunovant Sciences GmbH IMVT | NCT05517447 Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease | Thyroid Eye Disease | terminated | 109 |
| 2026-02-03 | P3 | Immunovant Sciences GmbH IMVT | NCT05524571 Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease | Thyroid Eye Disease | completed | 86 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.